Identifying a novel locus for psoriatic arthritis

被引:14
|
作者
Budu-Aggrey, Ashley [1 ,2 ,3 ]
Bowes, John [1 ]
Barton, Anne [1 ,2 ,3 ,4 ]
机构
[1] Univ Manchester, Arthrit Res UK Ctr Genet & Genom, Manchester M13 9PT, Lancs, England
[2] Cent Manchester Fdn Trust, NIHR Manchester Musculoskeletal Biomed Res Unit, Manchester, Lancs, England
[3] Univ Manchester, Manchester Acad Hlth Sci, Manchester M13 9PT, Lancs, England
[4] Cent Manchester Fdn Trust, NIHR Manchester Biomed Res Ctr, Kellgren Ctr Rheumatol, Manchester, Lancs, England
基金
英国医学研究理事会;
关键词
Psoriatic arthritis; psoriasis; specific risk loci; Immunochip; functional characterization; GENOME-WIDE ASSOCIATION; SUSCEPTIBILITY LOCI; DOUBLE-BLIND; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; METHOTREXATE; VARIANTS; EFFICACY; PHASE-3; PTPN22;
D O I
10.1093/rheumatology/kev273
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A number of studies have identified genetic risk loci for PsA, the majority of which also confer risk for psoriasis. The stronger heritability of PsA in comparison with psoriasis suggests that there should be risk loci that are specific for PsA. Identifying such loci could potentially inform therapy development to provide more effective treatments for PsA patients, especially with a considerable proportion being non-responsive to current therapies. Evidence of a PsA-specific locus has been previously found at HLA-B27 within the MHC region. A recent study has provided evidence of non-HLA risk loci that are specific for PsA at IL23R, PTPN22 and on chromosome 5q31. Functional characterization of these loci will provide further understanding of the pathways underlying PsA, and enable us to apply genetic findings for patient benefit.
引用
收藏
页码:25 / 32
页数:8
相关论文
共 50 条
  • [21] Current treatment options for psoriatic arthritis
    Koehm, Michaela
    Behrens, Frank
    AKTUELLE RHEUMATOLOGIE, 2019, 44 (05) : 339 - 344
  • [22] An update on the diagnosis and management of psoriatic arthritis
    Weger, W.
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2011, 146 (01): : 1 - 8
  • [23] Updated therapies for the management of Psoriatic Arthritis
    Toussi, Atrin
    Maverakis, Natalia
    Le, Stephanie T.
    Sarkar, Soumajyoti
    Raychaudhuri, Smriti K.
    Raychaudhuri, Siba P.
    CLINICAL IMMUNOLOGY, 2020, 220
  • [24] Dawn of Precision Medicine in Psoriatic Arthritis
    Miyagawa, Ippei
    Tanaka, Yoshiya
    FRONTIERS IN MEDICINE, 2022, 9
  • [25] A review of ixekizumab in the treatment of psoriatic arthritis
    O'Rielly, Darren D.
    Rahman, Proton
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2018, 14 (12) : 993 - 1002
  • [26] Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?
    Coates, Laura C.
    FitzGerald, Oliver
    Helliwell, Philip S.
    Paul, Carle
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2016, 46 (03) : 291 - 304
  • [27] A novel biological target for the treatment of psoriatic arthritis
    Spadaro, Antonio
    Montepaone, Monica
    Lubrano, Ennio
    IMMUNOTHERAPY, 2014, 6 (05) : 515 - 518
  • [28] Novel Treatments with Small Molecules in Psoriatic Arthritis
    Hansen, Renata Baronaite
    Kavanaugh, Arthur
    CURRENT RHEUMATOLOGY REPORTS, 2014, 16 (09)
  • [29] Adalimumab in Psoriatic Arthritis
    Salvarani, Carlo
    Pipitone, Nicolo
    Catanoso, Mariagrazia
    Chiarolanza, Ilaria
    Boiardi, Luigi
    Caruso, Andrea
    Pazzola, Giulia
    Macchioni, Pierluigi
    Di Lernia, Vito
    Albertini, Giuseppe
    JOURNAL OF RHEUMATOLOGY, 2012, 39 : 77 - 81
  • [30] Genetics of psoriatic arthritis
    O'Rielly, Darren D.
    Rahman, Proton
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2014, 28 (05): : 673 - 685